Pluristem Pronounces Appointments of Two Administrators to Board
Pluristem Pronounces Appointments of Two Administrators to Board
HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a number one regenerative drugs firm growing a platform of novel organic therapeutic merchandise, is happy to announce the appointment of Ms. Maital Shemesh-Rasmussen, a worldwide health-tech advertising and marketing strategist, and Mr. Rami Levi, a frontrunner in world advertising and marketing and worldwide governmental affairs, to its Board of Administrators.
Ms. Maital Shemesh-Rasmussen brings over 20 years of various commercialization expertise throughout numerous industries. Driving development within the health-tech sector, she has particularly centered on customized care and patient-centric, data-driven merchandise and value-based approaches. From 2018 to 2020, she served as World Head of Resolution Advertising at Roche Diagnostics Data Options, the place she outlined Roche’s new health-tech technique, bringing to market superior digital options and industrial fashions that positioned Roche as a world chief in well being know-how.
Key positions beforehand held by Ms. Shemesh-Rasmussen embody: Director of Strategic and Product Advertising at Oracle Healthcare and Precision Drugs (2013-2016), the place she drove penetration of the informatics, analytics and precision drugs market; Vice President of World Advertising at JPMorgan Chase Financial institution (2002-2007), the place she led world advertising and marketing and know-how innovation to generate multimillion-dollar development; Founder & CEO of Rasmussen Communications advertising and marketing company, the place she formed advertising and marketing methods and messaging for monetary, well being and know-how companies; a marketing consultant for startups; and a Board Member/Advertising Chair of Healthcare Data and Administration Methods Society Northern California. Her training features a BA in Behavioral Sciences, Magna Cum Laude, from Ben-Gurion College of the Negev, research for an MA in Political Science and Communication at Bar-Ilan College, and the Government Training Program in Technique, Finance and Pc Science at Columbia College, New York.
Mr. Rami Levi, Founder and President of Catalyst Group Worldwide, brings over 30 years of expertise in managing profitable worldwide tasks on 5 continents, partnering with world leaders, and connecting nations and business on a worldwide scale. His profession, spanning each the private and non-private sectors, has included 5 diplomatic missions on behalf of the State of Israel, in addition to the founding of a number of profitable firms. A number one skilled in worldwide affairs, world market growth, disaster administration, strategic planning and authorities regulatory administration, Mr. Levi has generated and managed main cross nations agreements through the years.
As Senior Deputy Normal & Head of Advertising Administration at Israel’s Ministry of Tourism, Mr. Levi led quite a few worldwide initiatives and world partnerships involving 42 governments and world-leading conglomerates. Within the personal sector, he based Catalyst Group, working as a marketing consultant for governments, world regulation companies, banks, tv networks and multinational NGOs. Mr. Levi’s holds an MA with Honors in Political Science from The Hebrew College of Jerusalem.
Pluristem Therapeutics Government Chairman of the Board, Zami Aberman, stated: “We’re very joyful to have Ms. Shemesh-Rasmussen and Mr. Levi on our Board of Administrators. Maital is an innovation-driven world Well being-Tech advertising and marketing strategist and an inspiring thinker, who’s enthusiastic about advancing healthcare via know-how. Rami is a most spectacular strategist and market developer, with confirmed enterprise acumen and intensive world connections. Collectively they carry immense information, expertise and networking potential throughout industries within the world market. We really feel sure that their joint capabilities will increase our strategic sources, enterprise growth and market penetration, contributing considerably to the success of Pluristem’s endeavors.”
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a number one regenerative drugs firm growing novel placenta-based cell remedy product candidates. The Firm has reported strong scientific trial information in a number of indications for its patented PLX cell product candidates and is at the moment conducting late stage scientific trials in a number of indications. PLX cell product candidates are believed to launch a variety of therapeutic proteins in response to irritation, muscle trauma, hematological issues and radiation harm. The cells are grown utilizing the Firm’s proprietary three-dimensional growth know-how and may be administered to sufferers off-the-shelf, with out tissue matching. Pluristem has a powerful mental property place; a Firm-owned and operated GMP-certified manufacturing and analysis facility; strategic relationships with main analysis establishments; and a seasoned administration workforce
Secure Harbor Assertion
This press launch incorporates categorical or implied forward-looking statements inside the Non-public Securities Litigation Reform Act of 1995 and different U.S. Federal securities legal guidelines. For instance, Pluristem is utilizing forward-looking statements when it discusses that its new administrators will improve the Board’s strategic capabilities in preparation for future development and commercialization endeavors. These forward-looking statements and their implications are primarily based on the present expectations of the administration of Pluristem solely, and are topic to numerous components and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements. The next components, amongst others, may trigger precise outcomes to vary materially from these described within the forward-looking statements: modifications in know-how and market necessities; Pluristem could encounter delays or obstacles in launching and/or efficiently finishing its scientific trials; Pluristem’s merchandise will not be authorized by regulatory businesses, Pluristem’s know-how will not be validated because it progresses additional and its strategies will not be accepted by the scientific group; Pluristem could also be unable to retain or entice key staff whose information is crucial to the event of its merchandise; unexpected scientific difficulties could develop with Pluristem’s course of; Pluristem’s merchandise could wind up being costlier than it anticipates; ends in the laboratory could not translate to equally good ends in actual scientific settings; outcomes of preclinical research could not correlate with the outcomes of human scientific trials; Pluristem’s patents will not be adequate; Pluristem’s merchandise could hurt recipients; modifications in laws could adversely influence Pluristem; incapability to well timed develop and introduce new applied sciences, merchandise and functions; lack of market share and strain on pricing ensuing from competitors, which may trigger the precise outcomes or efficiency of Pluristem to vary materially from these contemplated in such forward-looking statements. Besides as in any other case required by regulation, Pluristem undertakes no obligation to publicly launch any revisions to those forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the prevalence of unanticipated occasions. For a extra detailed description of the dangers and uncertainties affecting Pluristem, reference is made to Pluristem’s studies filed sometimes with the Securities and Change Fee.
Director of Investor Relations
A photograph accompanying this announcement is accessible at https://www.globenewswire.com/NewsRoom/AttachmentNg/52166deb-6ea3-4a6c-a235-94cac2bdec0d